Physician profile
Veronica Singh
NPI 1407543101
$7,184.96
in general payments reported to CMS, 2019-2025
25 companies · $2,945 in 2025
The $2,945 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,448 · 2024: $2,792 · 2025: $2,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,153 · Education: $31.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,153.16 |
| Education | $31.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,494.97 | 2023-2025 | Caplyta |
| Abbvie INC. | $1,124.65 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $817.82 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $814.80 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Corium, LLC | $599.15 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $438.45 | 2023-2025 | Loreev Xr, Gralise |
| Lundbeck LLC | $313.79 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $273.55 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $250.14 | 2024-2025 | Spravato, Invega Sustenna |
| Tris Pharma INC | $152.96 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Bausch Health US, LLC | $139.71 | 2023-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $137.09 | 2023-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $110.18 | 2023-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $108.46 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $81.64 | 2025 | Uzedy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $70.08 | 2025 | |
| Tempus Ai, INC | $45.11 | 2024 | |
| Indivior INC. | $40.70 | 2023-2024 | Sublocade |
| Ironshore Pharmaceuticals INC. | $35.11 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $28.42 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $28.12 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $26.47 | 2025 | Kisunla |
| Noven Therapeutics, LLC | $20.47 | 2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $16.75 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $16.37 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.